The MPS indication is streets behind the clinical development of OA, which they want to advance to full maturity before a deal. Incongruent, much?
Ann: Primary and Secondary endpoints met in MPS I Trial, page-36
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $68.29M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 20.5¢ | 19.0¢ | $156.2K | 795.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 152244 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 25584 | 1 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |